{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:56:59Z","timestamp":1793469419488,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Intramural research","award":["T32CA09168"],"award-info":[{"award-number":["T32CA09168"]}]},{"name":"National Institutes of Health and funding"},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Racial and ethnic variations in attribution of cervical precancer and cancer to human papillomavirus (HPV) types may result in different HPV vaccine protection, screening test coverage, and clinical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pooling data from 7 US studies, we calculated the proportional attribution of precancers and cancers to HPV types using HPV DNA typing from diagnosis. All statistical tests were 2-sided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For all racial and ethnic groups, most cases of cervical intraepithelial neoplasia grade 3 (CIN3) (84.2%-90.8% of\u20095526) and squamous cell carcinoma (SCC) (90.4%-93.8% of\u20091138) were attributed to types targeted by the 9-valent vaccine. A higher proportion of CIN3s were attributed to nonvaccine HPV types among non-Hispanic Black women (15.8%) compared with non-Hispanic Asian or Pacific Islander (9.7%; P\u2009=\u2009.002), non-Hispanic White (9.2%; P\u2009&amp;lt;\u2009.001), and Hispanic (11.3%; P\u2009=\u2009.004) women. The proportion of SCCs attributed to 9-valent types was similar by race and ethnicity (P\u2009=\u2009.80). A higher proportion of CIN3s were attributed to nonvaccine HPV35 among non-Hispanic Black (9.0%) compared with non-Hispanic Asian or Pacific Islander (2.2%), non-Hispanic White (2.5%), and Hispanic (3.0%; all P\u2009&amp;lt;\u2009.001) women. Compared with CIN3, the proportion of SCCs attributed to HPV35 among non-Hispanic Black women (3.2%) was lower and closer to other groups (0.3%-2.1%; P\u2009=\u2009.70).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The 9-valent HPV vaccine will prevent nearly all cervical precancers and invasive cancers among major racial and ethnic groups in the United States. Adding HPV35 to vaccines could prevent a small percentage of CIN3s and SCCs, with greater potential impact for CIN3s among Black women. HPV screening tests target high-risk HPV types, including HPV35. Future genotyping triage strategies could consider the importance of HPV35- and other HPV16-related types.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jnci\/djac034","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T04:15:00Z","timestamp":1644380100000},"page":"845-853","source":"Crossref","is-referenced-by-count":24,"title":["Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management"],"prefix":"10.1093","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-7706","authenticated-orcid":false,"given":"Jacqueline","family":"Mix","sequence":"first","affiliation":[{"name":"Division of Cancer Prevention and Control, Centers for Disease Control and Prevention , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Saraiya","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Control, Centers for Disease Control and Prevention , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D","family":"Hallowell","sequence":"additional","affiliation":[{"name":"Division\u2002 of Cancer Prevention and Control, Centers for Disease Control and Prevention , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Befano","sequence":"additional","affiliation":[{"name":"Information Management Services , Calverton, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-4331","authenticated-orcid":false,"given":"Li C","family":"Cheung","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-5635","authenticated-orcid":false,"given":"Elizabeth R","family":"Unger","sequence":"additional","affiliation":[{"name":"Divison of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia W","family":"Gargano","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E","family":"Markowitz","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention , Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-5985","authenticated-orcid":false,"given":"Philip E","family":"Castle","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD, USA"},{"name":"Division of Cancer Prevention, National Cancer Institute , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Raine-Bennett","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California , Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-4309","authenticated-orcid":false,"given":"Joan","family":"Walker","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center , Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Zuna","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center , \u2002Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schiffman","sequence":"additional","affiliation":[{"name":"Division\u2002 of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-0836","authenticated-orcid":false,"given":"Nicolas","family":"Wentzensen","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology\u2002 and Genetics, National Cancer Institute , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5259-6385","authenticated-orcid":false,"given":"Julia C","family":"Gage","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer\u2002 Institute , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"issue":"4","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens--part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Rr-05","key":"2023021701090886600_","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"issue":"11","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023021701090886600_","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023021701090886600_"},{"issue":"6","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1002\/cncr.28038","article-title":"Individual and geographic disparities in human papillomavirus types 16\/18 in high-grade cervical lesions","volume":"119","author":"Niccolai","year":"2013","journal-title":"Cancer"},{"key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/ijc.33033","article-title":"Association of HPV35 with cervical carcinogenesis among women of African ancestry: evidence of viral-host interaction with implications for disease intervention","author":"Pinheiro","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vaccine.2019.09.103","article-title":"Prevalence of human papillomavirus (HPV)-vaccine types by race and ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2\/3\/AIS), Alameda County, California, United States","volume":"38","author":"Saadeh","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"e34044","DOI":"10.1371\/journal.pone.0034044","article-title":"HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006","volume":"7","author":"Hariri","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"2023021701090886600_"},{"issue":"5","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jasc.2019.06.001","article-title":"A review of the FDA-approved molecular testing platforms for human papillomavirus","volume":"8","author":"Salazar","year":"2019","journal-title":"J Am Soc Cytopathol"},{"issue":"9","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-14-1353","article-title":"The role of human papillomavirus genotyping in cervical cancer screening: a large-scale evaluation of the cobas HPV test","volume":"24","author":"Schiffman","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/JCM.05989-11","article-title":"Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests","volume":"50","author":"Gage","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"7","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn510","article-title":"Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States","volume":"101","author":"Wheeler","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ijc.32340","article-title":"Cervical adenocarcinoma in situ: human papillomavirus types and incidence trends in five states, 2008-2015","volume":"146","author":"Cleveland","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1055-9965.EPI-14-0649","article-title":"HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States","volume":"24","author":"Hariri","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/ijc.24528","article-title":"Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants","volume":"125","author":"Wentzensen","year":"2009","journal-title":"Int J Cancer"},{"issue":"4","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"10","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/ijc.32919","article-title":"Identification of HPV genotypes causing cervical precancer using tissue-based genotyping","volume":"146","author":"Venetianer","year":"2020","journal-title":"Int J Cancer"},{"issue":"8","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10552-014-0406-2","article-title":"HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA","volume":"25","author":"Vidal","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"8","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncy.22267","article-title":"Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix","volume":"128","author":"Risley","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/ijc.28425","article-title":"Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa","volume":"134","author":"Denny","year":"2014","journal-title":"Int J Cancer"},{"issue":"4","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int J Cancer"},{"issue":"9","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"e107573","DOI":"10.1371\/journal.pone.0107573","article-title":"Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide","volume":"9","author":"Chan","year":"2014","journal-title":"PLoS One"},{"key":"2023021701090886600_","year":"2018"},{"issue":"2","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation","volume":"24","author":"Cheung","year":"2020","journal-title":"J Low Genit Tract Dis"},{"issue":"3","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jmv.10220","article-title":"Comparisons of HPV DNA detection by MY09\/11 PCR methods","volume":"68","author":"Castle","year":"2002","journal-title":"J Med Virol"},{"issue":"2","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PAS.0000000000000986","article-title":"International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2023021701090886600_","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/LGT.0b013e3182a577c7","article-title":"Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction","volume":"18","author":"Hopenhayn","year":"2014","journal-title":"J Low Genit Tract Dis"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djac034\/42958476\/djac034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/6\/845\/44035753\/djac034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/6\/845\/44035753\/djac034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:01:40Z","timestamp":1700200900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/114\/6\/845\/6530292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,2,17]]},"published-print":{"date-parts":[[2022,6,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djac034","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,2,17]]}}}